The use of high-flow nasal oxygen vs. standard oxygen therapy in hematological malignancy patients with acute respiratory failure in hematology wards

Conclusion: HFNC applied in wards is not superior to standard oxygen treatment for acute respiratory failure in hematological malignancy patients.Key words: Acute respiratory failure, high flow nasal oxygen, hematological malignancy

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Background/aim: High flow nasal cannula (HFNC) was mostly used in intensive care units (ICUs) with few studies in other departments.

📊

Key Findings & Data:Median age was 58.5 (18–86) years and APACHE II score was 17 (5–29).

💡

Conclusion & Impact:Conclusion: HFNC applied in wards is not superior to standard oxygen treatment for acute respiratory failure in hematological malignancy patients.Key words: Acute respiratory failure, high flow nasal oxygen, hematological malignancy

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Background/aim: High flow nasal cannula (HFNC) was mostly used in intensive care units (ICUs) with few studies in other departments. We hypothesized that HFNC applied at wards is beneficial for acute respiratory failure in hematological malignancy patients. Materials and methods: The study is a single center, randomized controlled study. Inclusion criteria were hypoxemic respiratory failure and hematological malignancy. Patients were randomized to either venturi mask/nasal cannula oxygen treatment or HFNC. Results: One hundred patients were included in the study. Median age was 58.5 (18–86) years and APACHE II score was 17 (5–29). HFNC group was 51 patients and the oxygen treatment group 49 patients. P/F ratios were similar between the groups throughout the study period. Endotracheal intubation was required in 10 (20.0%) patients in oxygen group and 17 (33.0%) patients in HFNC group (p = 0.14). A total of 17 (35.0%) patients in oxygen group and 17 (33.0%) patients in HFNC group received noninvasive mechanical ventilation (p = 0.97). Median VAS comfort scores at the 2nd and 24th hours were not different between groups. The 28-day mortality rate was 36.7% (18 deaths) in the standard group and 45.0% (23 deaths) in the HFNC group (p = 0.39). Conclusion: HFNC applied in wards is not superior to standard oxygen treatment for acute respiratory failure in hematological malignancy patients.Key words: Acute respiratory failure, high flow nasal oxygen, hematological malignancy

🔖

Cite This Article

KAYNAR, L., YÜKSEL, R. C., GÜNDOĞAN, K., TEMEL, Ş., SUNGUR, M., ESER, B., MENDİL, N. A. (2022). The use of high-flow nasal oxygen vs. standard oxygen therapy in hematological malignancy patients with acute respiratory failure in hematology wards. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 4, 1756–1763. https://ajindex.com/articles/609565

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (10)

Schmatz AI, Streubel B, Kretschmer-Chott E, Puspok A, Jager U et al. Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. Journal of Clinical Oncology 2011
29 (11): 1445-1451. doi:10.1200/jco.2010.32.9193 2. Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncology 2014
15 (9): 931- 942. doi:10.1016/s1470-2045(14)70282-7 3. Peigne V, Rusinova K, Karlin L, Darmon M, Fermand JP et al. Continued survival gains in recent years among critically ill myeloma patients. Intensive Care Medicine 2009
35 (3): 512- 518. doi:10.1007/s00134-008-1320-4 4. Van Vliet M, Verburg IW, Van den Boogaard M, De Keizer NF, Peek N et al. Trends in admission prevalence, illness severity and survival of haematological patients treated in Dutch intensive care units. Intensive Care Medicine 2014
40 (9): 1275-1284. https://doi.org/10.1007/s00134-014-3373-x 5. Azevedo LCP, Caruso P, Silva UVA, Torelly AP, Silva E et al. Outcomes for patients with cancer admitted to the ICU requiring ventilatory support: results from a prospective multicenter study. Chest 2014
146 (2): 257-266. doi:10.1378/ chest.13-1870 6. Molina R, Bernal T, Borges M, Zaragoza R, Bonastre J et al. Ventilatory support in critically ill hematology patients with respiratory failure. Critical Care 2012
16 (4): R133. doi:10.1186/cc11438 7. Adda M, Coquet I, Darmon M, Thiery G, Schlemmer B et al. Predictors of noninvasive ventilation failure in patients with hematologic malignancy and acute respiratory failure. Critical Care Medicine 2008
36 (10): 2766-2772. doi:10.1097/ ccm.0b013e31818699f6 8. Frat JP, Ragot S, Girault C, Perbet S, Prat G et al. Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post-hoc analysis of a randomised trial. Lancet Respiratory Medicine 2016
4 (8): 646-652. doi:10.1016/s2213-2600(16)30093-5 9. Hilbert G, Gruson D, Vargas F, Valentino R, Gbikpi-Benissan G et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. New England Journal of Medicine 2001
344 (7): 481-487. doi:10.1056/nejm200102153440703 10. Lemiale V, Mokart D, Resche-Rigon M, Pene F, Mayaux J et al. Effect of noninvasive ventilation vs oxygen thera